Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Head Lice
Interventions: Elimax Green Lotion with Emogreen, Walgreens Lice Killing Shampoo; Device · Drug
Lead sponsor: Oystershell NV; Industry
Eligibility: 6 Months and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Enid, Oklahoma

Conditions: Small Cell Lung Cancer
Interventions: Dinutuximab, Irinotecan, Topotecan; Biological · Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 40
States / cities: Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more

Conditions: Obesity, Pregnancy
Interventions: Dietary and lifestyle counseling; Behavioral
Lead sponsor: Carolinas Medical Center; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions: UCART123; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Rectal Adenocarcinoma
Interventions: APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Tucson, Arizona • Winston-Salem, North Carolina • Portland, Oregon + 1 more

Conditions: Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma, Advanced Leiomyosarcoma, Leiomyosarcoma Metastatic
Interventions: Lurbinectedin, Doxorubicin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 2 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 48
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Povetacicept; Drug
Lead sponsor: Alpine Immune Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more

Conditions: Hemophilia A
Interventions: rVIII-SingleChain, Octocog alfa; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: COVID-19
Interventions: ensovibep, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 27
States / cities: Jasper, Alabama • Colton, California • Fullerton, California + 21 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Mantle Cell Lymphoma, Refractory Lymphoma
Interventions: Acalabrutinib, Venetoclax, Obinutuzumab; Drug
Lead sponsor: Austin I Kim; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Macromastia (Symptomatic)
Interventions: Pectoral II Nerve Block, Post Operative Pain Relievers; Procedure · Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Substance-Related Disorders
Interventions: Transitional Case Management Study; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Hartford, Connecticut • Lexington, Kentucky + 1 more

Conditions: HIV -1 Infection
Interventions: BNT351, Placebo; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Obesity, Diabetes, Hypertension, Asthma/COPD With Tobacco Dependence
Interventions: CHW Goal Support; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Classical Hodgkin Lymphoma
Interventions: Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab, Vinblastine; Drug · Other · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sleep Disturbance
Interventions: Targeted Approaches for Promoting Adolescent Sleep (TAPAS), Sleep Monitoring Only; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 13 Years to 15 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Solid Malignancies
Interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: HIV Infections
Interventions: PRIDE, ePRIDE, Men's Health; Behavioral
Lead sponsor: San Francisco State University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis, Mosaicism
Interventions: Data and Specimen Collection; Genetic
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Postpartum Depression
Interventions: SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more

Conditions: Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma
Interventions: ADCT-402; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 4 more

Conditions: Status Asthmaticus
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Louisville, Kentucky • Detroit, Michigan • Cleveland, Ohio

Search by objective public record fields.

Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Lurbinectedin + Doxorubicin In Leiomyosarcoma

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Avo In R/R And Previously Untreated MCL

Pectoral Block in Breast Reduction for Pain Control

Transitional Case Management Study

A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Targeted Intervention for Insufficient Sleep Among Typically-Developing Adolescents

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

A Randomized Trial to Prevent HIV Among Gay Couples

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Intravenous Terbutaline in Severe Status Asthmaticus